Moderna ( NASDAQ:MRNA ) stock broke out for the first time in a year after beating Wall Street's first-quarter expectations as its second potential approval looms. The company hopes to win Food and Drug Administration approval for its RSV vaccine, which causes cold-like symptoms in most people but can be serious or deadly in babies and older adults. The FDA is due...
If you haven`t sold MRNA at all time high: Then analyzing the options chain and the chart patterns of MRNA Moderna prior to the earnings report this week, I would consider purchasing the 115usd strike price Calls with an expiration date of 2024-7-19, for a premium of approximately $8.00. If these options prove to be profitable prior to the earnings release, I...
This has nothing to do with politics, shut downs or any misinformation on COV1D. I went to fill my Adderall prescription at my local pharmacy and it took 30 minutes. I have never seen a bigger line in Safeway. I proceeded to ask the pharmacist, why are you so busy and when did it start? She responded with "vaccines are why, there is only MRNA to choose...
1. The RSI crosses over the Moving Average 2. RCI 3 Lines turn bullish 3. The chart breaks out of the resistance trend line. Let's see how this works out.
In a significant breakthrough for cancer treatment, Moderna's ( NASDAQ:MRNA ) individualized cancer vaccine, developed in collaboration with Merck, has shown remarkable promise in an early-stage trial targeting head and neck cancer. The encouraging results have ignited a surge in Moderna's stock price and injected fresh optimism into the field of oncology...
I have looked at the charts of Moderna and explained why I'm so bullish this stock as well as the general sector. We should expect a catalyst show up in the news in the very near future which should cause a big spike in this sector and that cannot be good for the overall market.
Moderna, Inc., a pioneering biotechnology firm, has been at the forefront of mRNA technology, revolutionizing the way we approach vaccines and therapeutics. As of now, Moderna's stock exhibits strong momentum, capturing the attention of investors and analysts alike. ### Investment Thesis **Strong Momentum:** Moderna's stock has shown impressive performance,...
Here's a small interesting history: In the late 19th century, stock trading took place through an archaic system of handwritten ledger entries and paper shares that had to be physically transported between offices. This cumbersome process led to frequent errors and delays. In 1887, a group of Wall Street clerks devised a more efficient method by setting up...
🔉Sound on!🔉 Thank you as always for watching my videos. I hope that you learned something very educational! Please feel free to like, share, and comment on this post. Remember only risk what you are willing to lose. Trading is very risky but it can change your life!
If one examines MRNA on the shorter term, the prospective is not so bright. s3.tradingview.com However, when one also examines the longer term, clear accumulation can be seen. s3.tradingview.com
NASDAQ:MRNA Bearish to Bullish Reversal A "Bearish to Bullish Reversal" in technical analysis for NASDAQ:MRNA suggests a shift in the stock's price movement pattern from a downward trend (bearish) to an upward trend (bullish). This reversal typically occurs after a period of decline, indicating that the stock may be transitioning from a bearish phase to a...
Moderna ( NASDAQ:MRNA ), a biotechnology company at the forefront of mRNA technology, is experiencing a significant surge in its stock price, climbing over 10% to surpass the $114 per share mark. This rally marks Moderna's highest level since January, reflecting a remarkable turnaround from its challenges in 2023. The resurgence of Moderna's stock can be...
NASDAQ:MRNA seems to have found its feet in wave 2. We should be now gearing up for wave 3, price action to get more promising upwards as we cross the diagonal resistance (red line). More on it: - iH&S shoulder also forming on weekly - While the monthly close of Jan wasn't promising, buyers stepped into Feb with a decent closure Disclaimer: This is not...
The biggest pharma giants are easy to recognize. Johnson and Johnson, Pfizer, Moderna, Merck & Co, Danaher Corp, Thermo Fisher Scientific. All medications and pharmaceutical drugs come out of these drug corporations. Lab equipment, medical research, vaccines, and other life science developments come out of these conglomerate pharma giants. Support and Resistance...
MRNA focuses on vaccine research and development and we are in the flu season an COVID is lurking in the shadows and trying to make a comback. It had an excellent earnings report and forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored VWAP and is at the level of the first upper VWAP while in side the high volume area...
The mRNA stock has exhibited a bullish flag breakout, following the identification of a falling wedge pattern. We anticipate a potential retracement towards the prominent key level near $130, which was established at the top.
Moderna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause. Unveiling the Numbers: Moderna's (...